Research

Focus on the pharmaceutical and biotech industry
Castleman Disease Explained

Castleman Disease Explained

Ruth-Anne Langan Pai, PhD Candidate and the collaborative research project lead for the Castleman Disease Collaborative Network (CDCN) provides an overview of Castleman disease.

The Latest Ibrutinib Data for Treating CLL

The Latest Ibrutinib Data for Treating CLL

James Dean, MD, senior medical director at Pharmacyclics provides an update on the most recent long-term data showing ibrutinib to be safe and effective for treating patients with chronic lymphatic leukemia (CLL).

What is a Rare Cancer?

What is a Rare Cancer?

Eric T. Wong, MD, Associate Professor at Harvard Medical School provides an overview of rare cancers. Unlike rare diseases that are defined as affecting less than 200,000 people in the United States, rare cancers are referred to those affecting less than 45,000 people in this country.

WORLDSymposium 2020 Preview

WORLDSymposium 2020 Preview

On February 10 – 13, 2020, leading lysosomal disease researchers will come together to share the latest scientific information about rare lysosomal conditions at WORLDSymposium.

Using Social Media Data to Improve Drug Development

Using Social Media Data to Improve Drug Development

Maria Picone is the mother of a child with Prader-Willi syndrome as well as founder/CEO of TREND Community – a company that collects anecdotal information from patients and caregivers so that the information can be quantified and assessed more efficiently.

Gene Therapy and Antibodies

Gene Therapy and Antibodies

Snejana Krassova, MD of Bayer Pharmaceuticals talks about the reality that some people have, or can develop, antibodies to the vectors that are commonly used for gene therapy.

Why Do Patients Participate in Clinical Trials?

Why Do Patients Participate in Clinical Trials?

Eric T. Wong, MD, Associate Professor at Harvard Medical School discusses some of the reasons that a patient will be interested in participating in a clinical trial, especially one involving a rare disease.

Ataluren, Deflazacort, and Duchenne Muscular Dystrophy

Ataluren, Deflazacort, and Duchenne Muscular Dystrophy

Claudio Santos, MD, MBA of PTC Therapeutics describes his company’s treatment options for Duchenne muscular dystrophy (DMD), including Translarna (ataluren) in Europe and Emflaza (defazacort) in the United States.

Fanconi Anemia

Fanconi Anemia

Gaurav Shah, MD, Chief Executive Officer & President of Rocket Pharmaceuticals explains Fanconi anemia, a rare blood disorder that his company is developing a gene therapy to treat.

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.